

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/543, C12Q 1/68 // G01N 33/78		A1	(11) International Publication Number: WO 95/18377 (43) International Publication Date: 6 July 1995 (06.07.95)
(21) International Application Number: PCT/GB94/02814		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 23 December 1994 (23.12.94)			
(30) Priority Data: 9326450.5 24 December 1993 (24.12.93) GB			
(71) Applicant (for all designated States except US): MULTILYTE LIMITED [GB/GB]; C/o Ventham & Company, 2nd floor, Kingsbourne House, 229-231 High Holborn, London WC1V 7DA (GB).		Published <i>With international search report.</i>	
(72) Inventor; and			
(75) Inventor/Applicant (for US only): EKINS, Roger, Philip [GB/GB]; Pondweed Place, Friday Street, Abinger, Common Dorking, Surrey RH5 6JR (GB).			
(74) Agent: ARMITAGE, Ian, M.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).			
(54) Title: BINDING ASSAY			
(57) Abstract			
<p>The present invention provides a method, device and test kit for determining the concentration of analytes in liquid samples in which the amount of binding agent having binding sites specific for a given analyte in the liquid sample is immobilised in a test zone on a solid support, the binding agent being divided into an array of spatially separated locations in the test zone. The concentration of the analyte is obtained by back-titrating the occupied binding agent with a developing agent having a marker and integrating the signal from each location in the array. The assay has the advantage of avoiding the increasing statistical errors as the area of a prior art microspot is reduced, while optimising signal-to-noise and the kinetics of the reaction between analyte and binding agent.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

BINDING ASSAYField of the Invention

5 The present invention relates to binding assays, eg for determining the concentration of analytes in liquid samples.

Background to the Invention

10

It is known to measure the concentration of an analyte, such as a drug or hormone, in a liquid sample by contacting the liquid with a binding agent having binding sites specific for the analyte, separating the binding agent having analyte bound to it and measuring a value representative of the proportion of the binding sites on the binding agent that are occupied by analyte (referred to as the fractional occupancy). Typically, the concentration of the analyte in the liquid sample can then be determined by comparing the fractional occupancy against values obtained from a series of standard solutions containing known concentrations of analyte.

25 In the past, the measurement of fractional occupancy has usually been carried out by back-titration with a labelled developing reagent using either so-called competitive or non-competitive methods.

30 In the competitive method, the binding agent having analyte bound to it is back-titrated, either simultaneously or sequentially, with a labelled developing agent, which is typically a labelled version of the analyte. The developing agent can be said to compete for the binding sites on the binding agent with the analyte whose concentration is being measured. The fraction of the binding sites which become occupied with the labelled analyte can then be related to the concentration of the analyte in the liquid sample as described above.

In the non-competitive method, the binding agent having analyte bound to it is back-titrated with a labelled developing agent capable of binding to either the bound analyte or the occupied binding sites on the binding agent.

5 The fractional occupancy of the binding sites can then be measured by detecting the presence of the labelled developing agent and, just as with competitive assays, related to the concentration of the analyte in the liquid sample as described above.

10

In both competitive and non-competitive methods, the developing agent is labelled with a marker. A variety of markers have been used in the past, for example radioactive isotopes, enzymes, chemiluminescent markers and fluorescent markers.

15

In the field of immunoassay, competitive immunoassays have in general been carried out in accordance with design principles enunciated by Berson and Yalow, for instance in "Methods in Investigative and Diagnostic Endocrinology" (1973), pages 111 to 116. Berson and Yalow proposed that in the performance of competitive immunoassays, maximum sensitivity is achieved if an amount of binding agent is used to bind approximately 30 to 50% of a low concentration of the analyte to be detected. In non-competitive immunoassays, maximum sensitivity is generally thought to be achieved by using sufficient binding agent to bind close to 100% of the analyte in the liquid sample. However, in both cases immunoassays designed in accordance with these widely accepted precepts require the volume of the sample to be known and the amount of binding agent used to be accurately known or known to be constant.

35

In International Patent Application WO84/01031, I disclosed that the concentration of an analyte in a liquid sample can be measured by contacting the liquid sample with a small amount of binding agent having binding sites specific for

the analyte. In this method, provided the amount of binding agent is small enough to have only an insignificant effect on the concentration of the analyte in the liquid sample, it is found that the fractional occupancy of the 5 binding sites on the binding agent by the analyte is effectively independent of the volume of the sample.

This approach is further refined in EP304,202 which discloses that the sensitivity and ease of development of 10 the assays in WO84/01031 is improved by using an amount of binding agent less than $0.1V/K$ moles located on a small area (or "microspot") of a solid support, where V is the volume of the sample and K is the equilibrium constant of the binding agent for the analyte.

15 In WO93/08472, I disclosed a method of further improving the sensitivity of binding assays by immobilising small amounts of binding agent at high density on a support in the form of a microspot. In this assay, a developing agent 20 comprising a microsphere containing a marker, eg a fluorescent dye, is used to back-titrate the binding agent after it has been contacted with the liquid sample containing the analyte. As the microsphere can contain a large number of molecules of fluorescent dye, the 25 sensitivity of the assay is improved as the signal from small amounts of analyte can be amplified. This amplification permits sensitive assays to be carried out even with microspots having an area of 1mm^2 or less and a surface density of binding agent in the range of 1000 to 30 $100000 \text{ molecules}/\mu\text{m}^2$.

Summary of the Invention

35 The present invention provides a method, device and test kit for carrying out a binding assay in which binding agent having binding sites specific for a given analyte in a liquid sample is immobilised in a test zone on a solid

support, the binding agent being divided into an array of spatially separated locations in the test zone, wherein the concentration of the analyte is obtained by integrating the signal from the locations in the array.

5

Accordingly, in one aspect, the present invention provides a method for determining the concentration of an analyte in a liquid sample comprising:

10 (a) locating binding agent having binding sites specific for the analyte in a test zone on a solid support, the binding agent being divided into an array of spatially separated locations;

15 (b) contacting the support with the liquid sample so that a fraction of the binding sites at each location become occupied by analyte;

(c) measuring a value of a signal representative of the fraction of the binding sites occupied by the analyte for each individual location in the array;

20 (d) integrating the signal value obtained for each location in the array to provide an integrated signal; and,

(e) comparing the integrated signal to corresponding values, obtained from a series of standard solutions containing known concentrations of analyte, to determine the concentration of the analyte in the liquid sample.

25

Thus, in the present invention, the values of the signal from an array of locations in the test zone are used to determine the concentration of a single analyte. This is in contrast to the approach described in EP304,202, in which the signal produced at a single location is used to determine the concentration of an analyte.

30 The array of locations of binding agent in the test zone can be viewed sequentially, eg using a confocal microscope, and the signal value from each location integrated to provide the integrated signal. Alternatively, the array of locations of binding agent in the test zone can be viewed

together, eg using a charge coupled device (CCD) camera, with the signal values from each location being measured simultaneously.

5 Preferably, the signals representative of the fraction of the binding sites occupied by binding agent at each location are measured by back-titrating the binding agent with a developing agent having a marker, the developing agent being capable of binding to unoccupied binding sites, 10 bound analyte or to occupied binding sites in a competitive or non-competitive method, as described above.

The marker on the developing agent can be a radioactive isotope, an enzyme, a chemiluminescent marker or a 15 fluorescent marker. The use of fluorescent dye markers is especially preferred as the fluorescent dyes can be selected to provide fluorescence of an appropriate colour range (excitation and emission wavelength) for detection. Fluorescent dyes include coumarin, fluorescein, rhodamine 20 and Texas Red. Fluorescent dye molecules having prolonged fluorescent periods can be used, thereby allowing time-resolved fluorescence to be used to measure the strength of the fluorescent signal after background fluorescence has decayed. Advantageously, marker can be incorporated within 25 or on the surface of latex microspheres attached to the developing agent. This allows a large quantity of marker to be associated with each molecule of developing agent, amplifying the signal produced by the developing agent.

30 Preferably, the locations are microspots and the assay is carried out using 4-40 (or more) microspots for each individual analyte, each microspot having an area less than 10000 μm^2 , the microspots being separated from each other by a distance of 100-1000 μm . The locations within the array 35 are referred to as "mini-microspots" in the relevant parts of the description that follow.

The present invention also allows the concentration of a plurality of analytes to be determined simultaneously by providing a plurality of test zones, each test zone having immobilised in it a total amount of binding agent having binding sites specific for a given analyte in a liquid sample, the binding agent being divided into an array of 5 spatially separated locations in the test zone.

Preferably, in accordance with EP304,202, the total amount 10 of binding agent in each array that is specific for a given analyte is less than $0.1 V/K$ moles, where V is the volume of the sample applied to the test zone and K is the association constant for analyte binding to the binding agent. This ensures that the "ambient analyte" conditions 15 described in WO83/01031 are fulfilled regardless of the analyte concentration.

One way of immobilising binding agent on a support at a 20 discrete location such as a microspot is to use technology comparable to the techniques used in ink-jet or laser printers, in the case of microspots typically providing spots having diameter of about $80\mu\text{m}$. Alternatively, if larger locations are required, a micropipette can be used 25 to control the amount of binding agent immobilised at a location on a support.

The present invention is based on the observation that as 30 the area of a microspot is reduced from a high value, such as 5mm^2 towards zero, the sensitivity of the binding assay (represented by the lower limit of detection) reaches a maximum when the microspot reaches a small, but finite area, typically around 0.1mm^2 . Further reducing the area of microspot leads to a reduction in the sensitivity of the binding assay. However, sensitivity is enhanced by 35 subdividing a microspot of any given area into multiple mini-microspots, such that the total coated area occupied by the mini-microspots, and hence the total amount of

binding agent remains the same.

In addition, the use of an array of microspots for each individual analyte allows the user to determine whether the 5 value obtained for any given microspot is in error by comparison with other microspots in the array.

In a further aspect, the present invention provides a device for determining the concentration of one or more 10 analytes in a liquid sample, the device comprising a solid support having one or more test zones, each test zone having immobilised in it an amount of binding agent having binding sites specific for a given analyte in a liquid sample, the binding agent being divided into an array of 15 spatially separated locations in the test zone, wherein the concentration of a given analyte is obtained by integrating signal values from each location in the array.

In a further aspect, the present invention provides a kit 20 for determining the concentration of one or more analytes in a liquid sample, the kit comprising:

(a) a device comprising a solid support having one or 25 more test zones, each test zone having immobilised in it an amount of binding agent having binding sites specific for a given analyte in a liquid sample, the binding agent being divided into an array of spatially separated locations in the test zone; and,

(b) one or more developing agents for determining the 30 fraction of the binding sites of the binding agent occupied by a given analyte, the developing agents having markers, the developing agents being capable of binding to bound analyte, or unoccupied or occupied binding sites of the binding agent;

35 wherein the concentration of a given analyte is obtained by integrating signal values from the markers of the developing agent at each location in the array.

Brief Description of the Drawings

5 The unexpected observation of a microspot area yielding a maximum sensitivity is thought to arise because a number of opposing effects combine to produce this outcome. These effects are explained with reference to the accompanying figures in which:

10 Figure 1 represents how the sensitivity of a binding assay typically changes with area of microspot at constant binding agent density;

Figure 2 represents the typical variation in signal-to-noise ratio as the area of a microspot changes;

15 Figure 3 represents how diffusion constraints on analyte binding to the binding agent change as the area of the microspot changes;

Figure 4 shows how the error in signal measurement changes as the area of the microspot changes;

20 Figure 5 shows a comparison between the microspot array of the present invention and a single microspot of the prior art; and

Figure 6 shows binding agent immobilised as an array of lines in an alternative embodiment of the invention.

Detailed Description

25 Note that in figures 1 to 4, the exact shape of the curves shown will depend on a number of parameters, including the physico-chemical properties (ie association and dissociation rate constants) of the binding agent, the viscosity of the analyte containing solution to which the microspot is exposed, the specific activity of the label used, etc.

35 In all the figures, value A denotes the area of a microspot typically used in the prior art (typically 1mm²). In all the figures, the density of binding agent is kept constant.

Figure 1 shows the experimentally observed variation of sensitivity as the area of a microspot is reduced. In the present context, sensitivity can be defined as the lower limit of detection which is given by the error (s.d) with which it is possible to measure zero signal. As figure 1 shows, as the area is reduced from value A, the sensitivity of the binding assay reaches a maximum and then declines as the area of the microspot is further reduced towards zero.

10

Some of the opposing factors leading to this observation are depicted in figures 2 to 4.

15

20

25

Figure 2 shows how the signal-to-noise ratio associated with the measurement of the occupancy of the binding sites of the binding agent changes as the size of the microspot decreases towards zero, assuming equilibrium has been reached. As microspot area is reduced from value A, the fractional occupancy of the binding sites of the binding agent reaches a plateau value as the concentration of binding agent falls below 0.01/K. Therefore, the signal per unit area from markers on developing agent used to measure the occupancy of the binding sites by analyte will also reach a plateau. As the background noise per unit area remains approximately constant, so the signal-to-noise ratio will likewise increase to a plateau value as the concentration of binding agent falls below 0.01/K.

30

35

Figure 3 shows how diffusion constraints change as the area of a microspot is reduced. "Diffusion constraints" restrict the rate at which analyte migrates towards and binds to the binding agent. As Figure 3 shows, the diffusion constraints decrease as microspot size decreases, ie the kinetics of the binding process are faster for smaller microspots, implying that thermodynamic equilibrium in the system is reached more rapidly.

On a molecular level, this phenomenon can be pictured as follows. When a microspot containing binding agent is placed in a liquid sample containing analyte, the binding agent binds analyte, depleting the local concentration of the analyte as compared to the liquid sample as a whole. This leads to a concentration gradient being established in the vicinity of the microspot until thermodynamic equilibrium is reached. This process is found to be slower for larger microspots the diffusion constraint being approximately proportional to microspot radius. When the occupancy of the binding sites on the binding agent has reached an equilibrium value, the concentration of analyte in the liquid sample is uniform. However, equilibrium is reached more rapidly in the case of microspots of smaller size, implying that, for any incubation time less than that required to reach equilibrium in the case of the larger spot, the fractional occupancy of the binding sites on the smaller spot is greater.

However, as microspot area decreases, so the amount of binding agent and the level of signal from developing agent will likewise decrease. This leads to an increase in the statistical errors in the measurement of the signal from a marker on a developing agent, which tend to infinity as the microspot area tends to zero (see figure 4).

It can be seen that a consideration of the signal-to-noise ratio and diffusion constraints indicate an increase in the sensitivity of a binding assay as the area of a microspot is decreased. However, these factors are opposed by an increase in the statistical error of signal measurement as the microspot area decreases. These factors combine to produce the observed variation of sensitivity with microspot area shown in figure 1. Thus, the overall consequence is that, as microspot area falls to zero, the binding assay becomes totally insensitive.

However, it is desirable to develop sensitive miniaturised binding assays using microspots of the smallest possible size containing vanishingly small amounts of binding agent, that have rapid kinetics to minimise the time taken to 5 carry out the assay.

The present invention improves sensitivity and reduces binding assay incubation times by exploiting the contradictory effects discussed above to maximal advantage. 10 This is done by sub-dividing the total amount of binding agent into an array of spatially separated locations such as "mini-microspots", to reduce diffusion constraints, and integrating the signals representative of the fractional occupancy of binding agent at each location to obtain a 15 total signal greater than would have been achieved by using a single microspot equal in area to the total area occupied by the minimicrospots comprising the minimicrospot array.

This implies, *inter alia*, that the total amount of binding 20 agent used can be made even smaller than in the prior art where a balance between kinetics and signal-to-noise relative to statistical errors had to be made to optimise sensitivity. The present invention therefore can improve the signal-to-noise ratio associated with measuring the 25 analyte bound to binding agent, whilst reducing the diffusion constraints associated with each microspot in the array. Moreover, the increasing statistical errors observed in the prior art as microspot size is reduced are obviated, as the signal generated from the occupied binding 30 sites by analyte in the individual microspots is integrated over the array to provide an integrated signal, thereby retaining the signal measurement advantage observed for larger microspots.

35 Figure 5 illustrates how a single microspot of the prior art can be divided into an array of 25 microspots containing an equivalent total amount of binding agent.

Nevertheless, other arrangements or geometries of binding agent providing assays yielding the same benefits can be envisaged, see for instance figure 6 which shows binding agent immobilised as lines forming a grid (see the shaded areas). This configuration likewise has the effect of reducing the diffusion constraints whilst maintaining the total area coated with binding agent (eg an antibody) to obviate the increasing statistical errors and associated loss of sensitivity observed as the amount of binding agent is reduced.

The amount and distribution of the binding agent in the locations comprising the array depends on a variety of factors including the diffusion characteristics of the analyte, the nature and viscosity of the liquid sample containing the analyte and the protocol used during incubation. However, given the guidance here the skilled person can readily determine, either experimentally or by computer modelling, the optimal arrangement or geometry of array for any given binding assay.

Example

Conjugation of Anti-TSH Mouse Monoclonal Antibody to
25 Fluorescent Hydrophilic Latex Microspheres

1. 10mg of fluorescent hydrophilic latex microspheres in 0.5ml double distilled water were added to 0.5ml of 1% Tween20, shaken for 15 min at room temperature and 30 centrifuged at 8°C for 10min at 20,000rpm in a TSE High-Spin 20 ultracentrifuge.
2. The pellet was dispersed in 2ml of 0.05M MES (2-[N-Morpholino] ethanesulfonic acid) buffer, pH6.1 and centrifuged.
- 35 3. Step 2 was repeated.
4. The pellet was dispersed in 0.8ml MES buffer.
5. 2mg of anti-TSH monoclonal developing antibody in

100 μ l were added to the microspheres and shaken for 15min at room temperature.

6. 100 μ l of 0.25% ethyl-3 (3-dimethyl amino) propyl carbodiimide hydrochloride were added to the mixture and 5 shaken for 2 hours at room temperature.

7. 10mg glycine in 100 μ l of MES buffer were added to the mixture, shaken for a further 30min and centrifuged.

8. The pellet was dispersed in 2ml of 1% BSA, shaken for 1 hour at room temperature and centrifuged.

10 9. The pellet was dispersed in 2ml of 1% BSA, shaken for 1 hour at room temperature and centrifuged.

10. The pellet was dispersed in 2ml of 0.1M phosphate buffer, pH7.4 and centrifuged.

11. Step 10 was repeated twice.

15 12. The pellet was dispersed in 2ml of 1% BSA containing 0.1% sodium azide and stored at 4°C.

Comparison of Kinetics of Micro Versus Mini-micro Capture Antibody Microspots in a Sandwich TSH Assay

20 1. Anti-TSH capture antibody microspots (diameter 1.1mm, area=10 6 μ m 2) were made by depositing 0.5 μ l of 200 μ g/ml antibody solution on each of 16 Dynatech black MicroFluor Microtitre wells, the droplets were aspirated immediately, 25 the wells blocked with SuperBlock from Pierce for 30min at room temperature and washed with 0.1M phosphate buffer, pH7.4.

30 2. The mini-microspots (diameter 0.16mm) were made using an piezoelectric ink-jet print-head with an anti-body solution concentration of 1mg/ml and droplets of approximately 100pl for an array of 49 (7 x 7) mini-microspots per microtitre wells (total coated antibody area = 10 6 μ m 2) for 16 wells. The wells were blocked with 35 SuperBlock and washed with phosphate buffer as above. The coated antibody density for both micro and mini-microspots are estimated to be 2 x 10 4 IgG/ μ m 2 .

3. 200 μ l of plasma containing 1 μ U/ml of TSH was added to all the microtitre wells and shaken at room temperature. At 30, 60, 120 min and 18 hours (overnight), four wells containing the microspots and mini-microspots were washed 5 with phosphate buffer containing 0.1% Tween20, then incubated with 200 μ l of anti-TSH developing antibody conjugated to hydrophilic latex microspheres in Tris-HCl buffer (50 μ g/ml) for 30 min at room temperature and washed 10 with phosphate-Tween20 buffer. The wells were then scanned with a laser scanning confocal microscope equipped with an Argon/Krypton laser.

Results

15	Sample	Total Fluorescent Signal (arbitrary units)	
	incubation	Microspot	Mini-microspot
	times (mins)		
20	30	85 \pm 7	111 \pm 13
	60	118 \pm 15	149 \pm 16
	120	141 \pm 21	178 \pm 16
25	Overnight	185 \pm 20	191 \pm 23

Conclusion

30 Significantly higher mean responses were observed between 30 and 120 mins in the mini-micro spot samples, while the overnight controls did not show significant differences. This demonstrates that the mini-microspots have faster kinetic for the association of analyte with the capture antibody, and could be used to reduce incubation times.

CLAIMS

1. A method for determining the concentration of an analyte in a liquid sample comprising:

5 (a) locating binding agent having binding sites specific for the analyte in a test zone on a solid support, the binding agent being divided into an array of spatially separated locations;

10 (b) contacting the support with the liquid sample so that a fraction of the binding sites at each location become occupied by analyte;

15 (c) measuring a value of a signal representative of the fraction of the binding sites occupied by the analyte for each individual location in the array;

(d) integrating the signal value obtained for each location in the array to provide an integrated signal; and,

20 (e) comparing the integrated signal to corresponding values, obtained from a series of standard solutions containing known concentrations of analyte, to determine the concentration of the analyte in the liquid sample.

2. A method according to claim 1 wherein the fraction of the binding sites occupied by the analyte is measured by back-titrating the binding agent with a developing agent labelled with a marker, the developing agent being capable of binding to unoccupied binding sites, to bound analyte or to the occupied binding sites, the marker providing the values of signal representative of the fraction of the binding sites occupied by analyte.

30

3. A method according to claim 1 or claim 2 wherein the binding agent is immobilised in an array of between 4 and 40 locations.

35

4. A method according to any one of the preceding claims wherein the locations have an area of about $10000\mu\text{m}^2$, the locations being separated from each other by a distance of

100 to 1000 μ m.

5. A method according to any one of the preceding claims wherein the total amount of binding agent in a test zone is less than 0.1V/K moles, where V is the volume of the liquid sample and K is the association constant for analyte binding to the binding agent.

10. 6. A method according to any one of the preceding claims for determining the concentration of a plurality of different analytes in the liquid sample, using a plurality of binding agents, each binding agent having binding sites specific for a given analyte and being immobilised as an array of locations.

15

7. A method according to any one of the preceding claims wherein the binding agent is an antibody having binding sites for an antigen or an oligonucleotide capable of binding to a nucleic acid analyte.

20


8. A kit for determining the concentration of one or more analytes in a liquid sample, the kit comprising:

25 (a) a device comprising a solid support having one or more test zones, each test zone having immobilised in it an amount of binding agent having binding sites specific for a given analyte in a liquid sample, the binding agent being divided into an array of spatially separated locations in the test zone; and,


30 (b) one or more developing agents for determining the fraction of the binding sites of the binding agent occupied by a given analyte, the developing agents having markers, the developing agents being capable of binding to bound analyte, or unoccupied or occupied binding sites of the binding agent;

35 wherein the concentration of a given analyte is obtained by integrating signal values from the markers of the developing agent at each location in the array.

9. A device for determining the concentration of one or more analytes in a liquid sample, the device comprising a solid support having one or more test zones, each test zone having immobilised in it an amount of binding agent having 5 binding sites specific for a given analyte in a liquid sample, the binding agent being divided into an array of spatially separated locations in the test zone, wherein the concentration of a given analyte is obtained by integrating signal values from each location in the array.





Area of microspot

Fig.1.

Area of microspot

Fig.2.

SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)





Fig.5.




Fig.6.

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/GB 94/02814

A. CLASSIFICATION OF SUBJECT MATTER

G 01 N 33/543, C 12 Q 1/68, //G 01 N 33/78

According to International Patent Classification (IPC) or to both national classification and IPC

6

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G 01 N, C 12 Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A, 88/01 058 (EKINS) 11 February 1988 (11.02.88), abstract; claims. --	1, 2, 8
A	WO, A, 93/08 472 (MULTILYTE LIMITED) 29 April 1993 (29.04.93), the whole document (cited in the application). --	1, 2, 7, 8
A	EP, A, 0 304 202 (EKINS) 22 February 1989 (22.02.89), the whole document (cited in the application). ----	1, 2, 5, 8

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

06 March 1995

Date of mailing of the international search report

29.03.95

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

SCHNASS e.h.

ANHANG

zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr.

ANNEX

to the International Search Report to the International Patent Application No.

ANNEX

au rapport de recherche international relatif à la demande de brevet international n°

PCT/GB 94/02814 SAE 101815

In diesem Anhang sind die Mitglieder der Patentfamilien der im obengenannten internationalen Recherchenbericht angeführten Patentdokumente angegeben. Diese Angaben dienen nur zur Unter-richtung und erfolgen ohne Gewähr.

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The Office is in no way liable for these particulars which are given merely for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visé ci-dessus. Les renseignements fournis sont donnés à titre indicatif et n'engagent pas la responsabilité de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 8801058	11-02-88	EP A1 271974 EP B1 271974 AT E 86385 AU A1 77559/87 AU B2 614935 DK A 1830/88 DK AO 1830/88 FI A 890526 FI AO 890526 FI B 92881 FI C 92881 JP T2 1503405 NO A 881241 NO AO 881241 NO B 172517 NO C 172517 US A 5171695 CA A1 1284620 DE CO 3704465 DE T2 3784465 EP A1 318491 ES T3 2039444 GB AO 8619206 ZA A 8705825 AT E 78101 AU A1 22534/88 AU B2 625052 BR A 8807644 CA A1 1334278 DE CO 3872621 DK AO 293/90 DK A 293/90 EP A1 304202 EP A1 375700 EP B1 304202 FI AO 900537 HU AO 884720 HU A2 54239 NO A 900534 NO AO 900534 WO A1 8901157 ZA A 8805825 DE T2 3872621 DK B 164944 DK C 164944 ES T3 2034245 FI B 92110 FI C 92110 GB AO 8803000 JP T2 3503081	22-06-88 03-03-93 15-03-93 24-02-88 19-09-91 05-04-88 05-04-88 03-02-89 03-02-89 30-09-94 10-01-95 16-11-89 21-03-88 21-03-88 19-04-93 28-07-93 15-12-92 04-06-91 08-04-93 17-06-93 07-06-89 01-10-93 17-09-86 27-04-88 15-07-92 01-03-89 02-07-92 07-08-90 07-02-95 13-08-92 05-02-90 05-04-90 22-02-89 04-07-90 08-07-92 05-02-90 28-09-90 28-01-91 05-02-90 05-02-90 09-02-89 26-04-89 18-02-93 14-09-92 01-02-93 01-04-93 15-06-94 26-09-94 09-03-88 11-07-91
WO A1 9308472	29-04-93	GB AO 9221094 AU A1 28720/92 EP A1 608370 GB AO 9121873	18-11-92 21-05-93 03-08-94 27-11-91
EP A1 304202	22-02-89	WO A1 8801058 AT E 78101 AU A1 77559/87 AU A1 22534/88 AU B2 614935 AU B2 625052 BR A 8807644 CA A1 1334278	11-02-88 15-07-92 24-02-88 01-03-89 19-09-91 02-07-92 07-08-90 07-02-95

DE	CO	3872621	13-08-92
DK	A	183078U	05-04-88
DK	AO	1830788	05-04-88
DK	AO	293/90	05-02-90
DK	A	293/90	05-04-90
EP	A1	375700	04-07-90
EP	B1	304202	08-07-92
FI	A	890526	03-02-89
FI	AO	890526	03-02-89
FI	AO	900557	05-02-90
HU	AO	884720	28-09-90
HU	A2	54239	28-01-91
NO	A	900534	05-02-90
NO	AO	900534	05-02-90
WO	A1	8901157	09-02-89
ZA	A	8805825	26-04-89
EP	A1	318491	07-06-89
FI	B	92881	30-09-94
FI	C	92881	10-01-95
JP	T2	1503405	16-11-89
NO	A	881241	21-03-88
NO	AO	881241	21-03-88
NO	B	172517	19-04-93
NO	C	172517	28-07-93
US	A	5171695	15-12-92
DE	T2	3872621	18-02-93
DK	B	164944	14-09-92
DK	C	164944	01-02-93
ES	T2	2034245	01-04-93
FI	B	92110	15-06-94
FI	C	92110	26-09-94
GB	AO	8803000	09-03-88
JP	T2	3503081	11-07-91
EP	A1	271974	22-06-88
EP	B1	271974	03-03-93
AT	E	86385	15-03-93
CA	A1	1284620	04-06-91
DE	CO	3784465	08-04-93
DE	T2	3784465	17-06-93
ES	T2	2039444	01-10-93
GB	AO	8819206	17-09-86
ZA	A	8705825	27-04-88

